The hemostatic agents market size has grown strongly in recent years. It will grow from $4.42 billion in 2025 to $4.66 billion in 2026 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to limited variety of hemostatic agents, reliance on traditional thrombin and gelatin products, increasing number of surgical procedures, growing hospital infrastructure, awareness of blood loss management.
The hemostatic agents market size is expected to see strong growth in the next few years. It will grow to $5.71 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to development of recombinant and sprayable fibrin sealants, expansion in minimally invasive and orthopedic surgeries, rising demand for multi-agent and combination hemostats, increased adoption in plastic and neurosurgery applications, regulatory emphasis on sterility and biocompatibility. Major trends in the forecast period include rising demand for advanced hemostatic agents in surgical procedures, increasing adoption of combination and multi-agent hemostats, growth in fibrin sealants and biologically derived products, expansion of hemostats use in trauma and cardiovascular surgeries, enhanced focus on safety, sterility, and regulatory compliance.
The rising number of surgical procedures is anticipated to drive the growth of the hemostatic agents market in the coming years. Surgical procedures involve medical interventions carried out by healthcare professionals using specialized tools to treat, repair, or remove parts of the body for health-related purposes. The increase in surgical procedures is primarily due to the growing prevalence of chronic conditions, which often require surgical intervention to manage health issues and enhance patient outcomes. Hemostatic agents play a crucial role in surgeries, as they help control bleeding rapidly, minimizing blood loss and improving visibility in the surgical area for more precise operations. For example, in October 2025, data from the UK Health Security Agency (UKHSA), a UK-based national public health organization, indicated that during the 2023-24 period, 135,619 operations were reported, with 1,276 surgical site infections (SSIs) identified during inpatient care or readmission, reflecting an 8.4% rise in submissions compared to the previous year. Hence, the growing number of surgical procedures is fueling the expansion of the hemostatic agents market.
Key players in the hemostatic agents market are developing innovative products, such as collagen-based hemostats, designed to provide rapid and effective bleeding control and tissue sealing in both open and minimally invasive surgeries. Collagen-based hemostats consist of purified collagen materials that aid hemostasis by enhancing the body’s natural clotting at wound or incision sites. For instance, in March 2025, Baxter, a US healthcare company, introduced HEMOPATCH Sealing Hemostat, an absorbable collagen-based pad. This advanced pad features a dual-action system that combines a collagen matrix with an NHS-PEG layer, which forms a hydrogel when it contacts moisture, enabling fast sealing of bleeding areas. It adheres strongly to wet tissues, making it effective in both open and minimally invasive surgical procedures where other agents may fall short. The patch achieves hemostasis in less than two minutes without requiring temperature-controlled storage or special preparation, simplifying surgical workflows. It naturally dissolves within 6 to 8 weeks and can be stored at room temperature for up to three years, meeting critical clinical and storage needs.
In May 2025, Merit Medical Systems Inc., a US medical device manufacturer, acquired Biolife Delaware LLC for an undisclosed sum. This acquisition positions Merit to offer a wider range of products that enhance consistency and efficiency in post-procedure care. It also strengthens Merit’s portfolio with specialized hemostatic solutions suitable for various clinical applications, including bleeding management from vascular closures and indwelling catheters. Biolife Delaware LLC is a US-based producer of hemostatic agents.
Major companies operating in the hemostatic agents market are Pfizer Inc., Johnson & Johnson Services Inc., Becton Dickinson & Co., CSL Ltd., Baxter International Inc., Teleflex Inc., Integra LifeSciences Holdings Corp., Gelita Medical, Artivion Inc., B. Braun Melsungen AG, Advanced Medical Solutions Group Plc, Z‑Medica, Marine Polymer Technologies Inc., MedTrade Products Ltd., Samyang Holdings Corp., Vascular Solutions Pc, BioCer Entwicklungs GmbH, Starch Medical Inc., Arch Therapeutics Inc., Medcura Inc., Biom’Up SAS.
North America was the largest region in the hemostatic agents market in 2025. The regions covered in the hemostatic agents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hemostatic agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the hemostatic agents market by raising costs for imported raw materials such as collagen, gelatin, and recombinant proteins. Segments like fibrin sealants, combination hemostats, and oxidized regenerated cellulose-based products are most affected, particularly in regions such as North America and Asia-Pacific where import dependence is high. This has increased production costs and affected supply chain efficiency. On the positive side, tariffs have encouraged domestic manufacturing, local sourcing of raw materials, and innovation in multi-agent hemostatic formulations.
The hemostatic agents market research report is one of a series of new reports that provides hemostatic agents market statistics, including hemostatic agents industry global market size, regional shares, competitors with a hemostatic agents market share, detailed hemostatic agents market segments, market trends and opportunities, and any further data you may need to thrive in the hemostatic agents industry. This hemostatic agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Hemostatic agents are specialized substances designed to assist the body’s natural blood clotting process by controlling and stopping bleeding. They work by interacting with different components of the coagulation system to promote the formation of a stable clot at the site of vascular injury.
The primary types of hemostatic agents include thrombin-based, gelatin-based, collagen-based, oxidized regenerated cellulose-based, combination hemostats, fibrin sealants, and others. Thrombin-based hemostats use thrombin, a natural blood enzyme, to quickly halt bleeding by accelerating clot formation. These agents are used in trauma care, cardiovascular surgery, general surgery, plastic surgery, orthopedic surgery, neurosurgery, and more, serving end users such as hospitals, surgical centers, nursing homes, and others.
The hemostatic agents market consists of sales of chitosan-based hemostats, flowable hemostats, synthetic polymer-based hemostats, topical absorbable hemostats, and adhesive hemostatic films. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The hemostatic agents market size is expected to see strong growth in the next few years. It will grow to $5.71 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to development of recombinant and sprayable fibrin sealants, expansion in minimally invasive and orthopedic surgeries, rising demand for multi-agent and combination hemostats, increased adoption in plastic and neurosurgery applications, regulatory emphasis on sterility and biocompatibility. Major trends in the forecast period include rising demand for advanced hemostatic agents in surgical procedures, increasing adoption of combination and multi-agent hemostats, growth in fibrin sealants and biologically derived products, expansion of hemostats use in trauma and cardiovascular surgeries, enhanced focus on safety, sterility, and regulatory compliance.
The rising number of surgical procedures is anticipated to drive the growth of the hemostatic agents market in the coming years. Surgical procedures involve medical interventions carried out by healthcare professionals using specialized tools to treat, repair, or remove parts of the body for health-related purposes. The increase in surgical procedures is primarily due to the growing prevalence of chronic conditions, which often require surgical intervention to manage health issues and enhance patient outcomes. Hemostatic agents play a crucial role in surgeries, as they help control bleeding rapidly, minimizing blood loss and improving visibility in the surgical area for more precise operations. For example, in October 2025, data from the UK Health Security Agency (UKHSA), a UK-based national public health organization, indicated that during the 2023-24 period, 135,619 operations were reported, with 1,276 surgical site infections (SSIs) identified during inpatient care or readmission, reflecting an 8.4% rise in submissions compared to the previous year. Hence, the growing number of surgical procedures is fueling the expansion of the hemostatic agents market.
Key players in the hemostatic agents market are developing innovative products, such as collagen-based hemostats, designed to provide rapid and effective bleeding control and tissue sealing in both open and minimally invasive surgeries. Collagen-based hemostats consist of purified collagen materials that aid hemostasis by enhancing the body’s natural clotting at wound or incision sites. For instance, in March 2025, Baxter, a US healthcare company, introduced HEMOPATCH Sealing Hemostat, an absorbable collagen-based pad. This advanced pad features a dual-action system that combines a collagen matrix with an NHS-PEG layer, which forms a hydrogel when it contacts moisture, enabling fast sealing of bleeding areas. It adheres strongly to wet tissues, making it effective in both open and minimally invasive surgical procedures where other agents may fall short. The patch achieves hemostasis in less than two minutes without requiring temperature-controlled storage or special preparation, simplifying surgical workflows. It naturally dissolves within 6 to 8 weeks and can be stored at room temperature for up to three years, meeting critical clinical and storage needs.
In May 2025, Merit Medical Systems Inc., a US medical device manufacturer, acquired Biolife Delaware LLC for an undisclosed sum. This acquisition positions Merit to offer a wider range of products that enhance consistency and efficiency in post-procedure care. It also strengthens Merit’s portfolio with specialized hemostatic solutions suitable for various clinical applications, including bleeding management from vascular closures and indwelling catheters. Biolife Delaware LLC is a US-based producer of hemostatic agents.
Major companies operating in the hemostatic agents market are Pfizer Inc., Johnson & Johnson Services Inc., Becton Dickinson & Co., CSL Ltd., Baxter International Inc., Teleflex Inc., Integra LifeSciences Holdings Corp., Gelita Medical, Artivion Inc., B. Braun Melsungen AG, Advanced Medical Solutions Group Plc, Z‑Medica, Marine Polymer Technologies Inc., MedTrade Products Ltd., Samyang Holdings Corp., Vascular Solutions Pc, BioCer Entwicklungs GmbH, Starch Medical Inc., Arch Therapeutics Inc., Medcura Inc., Biom’Up SAS.
North America was the largest region in the hemostatic agents market in 2025. The regions covered in the hemostatic agents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hemostatic agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the hemostatic agents market by raising costs for imported raw materials such as collagen, gelatin, and recombinant proteins. Segments like fibrin sealants, combination hemostats, and oxidized regenerated cellulose-based products are most affected, particularly in regions such as North America and Asia-Pacific where import dependence is high. This has increased production costs and affected supply chain efficiency. On the positive side, tariffs have encouraged domestic manufacturing, local sourcing of raw materials, and innovation in multi-agent hemostatic formulations.
The hemostatic agents market research report is one of a series of new reports that provides hemostatic agents market statistics, including hemostatic agents industry global market size, regional shares, competitors with a hemostatic agents market share, detailed hemostatic agents market segments, market trends and opportunities, and any further data you may need to thrive in the hemostatic agents industry. This hemostatic agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Hemostatic agents are specialized substances designed to assist the body’s natural blood clotting process by controlling and stopping bleeding. They work by interacting with different components of the coagulation system to promote the formation of a stable clot at the site of vascular injury.
The primary types of hemostatic agents include thrombin-based, gelatin-based, collagen-based, oxidized regenerated cellulose-based, combination hemostats, fibrin sealants, and others. Thrombin-based hemostats use thrombin, a natural blood enzyme, to quickly halt bleeding by accelerating clot formation. These agents are used in trauma care, cardiovascular surgery, general surgery, plastic surgery, orthopedic surgery, neurosurgery, and more, serving end users such as hospitals, surgical centers, nursing homes, and others.
The hemostatic agents market consists of sales of chitosan-based hemostats, flowable hemostats, synthetic polymer-based hemostats, topical absorbable hemostats, and adhesive hemostatic films. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Hemostatic Agents Market Characteristics
3. Hemostatic Agents Market Supply Chain Analysis
4. Global Hemostatic Agents Market Trends and Strategies
5. Hemostatic Agents Market Analysis of End Use Industries
7. Global Hemostatic Agents Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Hemostatic Agents Total Addressable Market (TAM) Analysis for the Market
9. Hemostatic Agents Market Segmentation
10. Hemostatic Agents Market Regional and Country Analysis
11. Asia-Pacific Hemostatic Agents Market
12. China Hemostatic Agents Market
13. India Hemostatic Agents Market
14. Japan Hemostatic Agents Market
15. Australia Hemostatic Agents Market
16. Indonesia Hemostatic Agents Market
17. South Korea Hemostatic Agents Market
18. Taiwan Hemostatic Agents Market
19. South East Asia Hemostatic Agents Market
20. Western Europe Hemostatic Agents Market
21. UK Hemostatic Agents Market
22. Germany Hemostatic Agents Market
23. France Hemostatic Agents Market
24. Italy Hemostatic Agents Market
25. Spain Hemostatic Agents Market
26. Eastern Europe Hemostatic Agents Market
27. Russia Hemostatic Agents Market
28. North America Hemostatic Agents Market
29. USA Hemostatic Agents Market
30. Canada Hemostatic Agents Market
31. South America Hemostatic Agents Market
32. Brazil Hemostatic Agents Market
33. Middle East Hemostatic Agents Market
34. Africa Hemostatic Agents Market
36. Hemostatic Agents Market Competitive Landscape and Company Profiles
37. Hemostatic Agents Market Other Major and Innovative Companies
40. Hemostatic Agents Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Hemostatic Agents Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses hemostatic agents market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for hemostatic agents? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hemostatic agents market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Thrombin-Based Hemostats; Gelatin-Based Hemostats; Collagen-Based Hemostats; Oxidized Regenerated Cellulose-Based Hemostats; Combination Hemostats; Fibrin Sealants; Other Types2) By Application: Trauma; Cardiovascular Surgery; General Surgery; Plastic Surgery; Orthopedic Surgery; Neurosurgery; Other Applications
3) By End-User: Hospitals; Surgery Centers; Nursing Homes; Other End Users
Subsegments:
1) By Thrombin-Based Hemostats: Bovine Thrombin; Human Thrombin; Poxidized Regenerated Cellulose (Orc)Ine Thrombin; Combined Thrombin Products2) By Gelatin-Based Hemostats: Absorbable Gelatin Sponges; Gelatin Powder; Gelatin Paste; Gelatin With Thrombin
3) By Collagen-Based Hemostats: Collagen Sponges; Collagen Powder; Collagen With Thrombin; Collagen Sheets Or Patches
4) By Oxidized Regenerated Cellulose-Based Hemostats: Oxidized Regenerated Cellulose (ORC) Pads; Oxidized Regenerated Cellulose (ORC) Mesh; Oxidized Regenerated Cellulose (ORC) Powder; Oxidized Regenerated Cellulose (ORC) With Other Active Agents
5) By Combination Hemostats: Gelatin And Thrombin Combinations; Collagen And Thrombin Combinations; Oxidized Regenerated Cellulose (ORC) And Thrombin Combinations; Multi-Agent Combinations
6) By Fibrin Sealants: Human Plasma-Derived Fibrin Sealants; Recombinant Fibrin Sealants; Sprayable Fibrin Sealants; Liquid Fibrin Sealants; Fibrin Sealants With Antimicrobials
7) By Other Types: Polysaccharide-Based Hemostats; Synthetic Polymer-Based Hemostats; Microfibrillar Collagen Hemostats; Chitosan-Based Hemostats; Calcium-Based Hemostats
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Becton Dickinson & Co.; CSL Ltd.; Baxter International Inc.; Teleflex Inc.; Integra LifeSciences Holdings Corp.; Gelita Medical; Artivion Inc.; B. Braun Melsungen AG; Advanced Medical Solutions Group Plc; Z‑Medica; Marine Polymer Technologies Inc.; MedTrade Products Ltd.; Samyang Holdings Corp.; Vascular Solutions Pc; BioCer Entwicklungs GmbH; Starch Medical Inc.; Arch Therapeutics Inc.; Medcura Inc.; Biom’Up SAS.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Hemostatic Agents market report include:- Pfizer Inc.
- Johnson & Johnson Services Inc.
- Becton Dickinson & Co.
- CSL Ltd.
- Baxter International Inc.
- Teleflex Inc.
- Integra LifeSciences Holdings Corp.
- Gelita Medical
- Artivion Inc.
- B. Braun Melsungen AG
- Advanced Medical Solutions Group Plc
- Z‑Medica
- Marine Polymer Technologies Inc.
- MedTrade Products Ltd.
- Samyang Holdings Corp.
- Vascular Solutions Pc
- BioCer Entwicklungs GmbH
- Starch Medical Inc.
- Arch Therapeutics Inc.
- Medcura Inc.
- Biom’Up SAS.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 4.66 Billion |
| Forecasted Market Value ( USD | $ 5.71 Billion |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
